Dendritic cell-regulatory T-cell interactions control self-directed immunity

Immunology and Cell Biology

Volumn 85, Issue 8, 2007, Pages 575-581

  Lange, Christian ^a   Dürr, Michael ^a   Doster, Hong ^a   Melms, Arthur ^a   Bischof, Felix ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

CD4+CD25+ regulatory T cells; Dendritic cells; Peripheral tolerance

Indexed keywords

TRYPTOPHAN; TUMOR ANTIGEN;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER; CATABOLISM; CD4+ CD25+ T LYMPHOCYTE; CELL INTERACTION; CELL MATURATION; CELL SPECIFICITY; CELL TYPE; CLONAL ANERGY; DENDRITIC CELL; DOWN REGULATION; GENE DELETION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; THYMUS; TRANSPLANTATION;

EID: 36849042748     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/sj.icb.7100088     Document Type: Review

References (142)

1. Janeway Jr CA, Bottomly K. Signals and signs for lymphocyte responses. Cell 1994; 76: 275-285.
2. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233-258.
3. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685-711.
4. Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 2007; 7: 19-30.
5. Heath WR, Belz GT, Behrens GM, Smith CM, Forehan SP, Parish IA et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004; 199: 9-26.
6. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002; 2: 151-161.
7. Yrlid U, Jenkins CD, MacPherson GG. Relationships between distinct blood monocyte subsets and migrating intestinal lymph dendritic cells in vivo under steady-state conditions. J Immunol 2006; 176: 4155-4162.
8. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284: 1835-1837.
9. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184: 747-752.
10. Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 1997; 185: 1101-1111.
11. O'Keeffe M, Hochrein H, Vremec D, Caminschi I, Miller JL, Anders EM et al. Mouse plasmacytoid cells: long-lived cells, heterogeneous in surface phenotype and function, that differentiate into CD8(+) dendritic cells only after microbial stimulus. J Exp Med 2002; 196: 1307-1319.
12. Fugmann SD, Lee AI, Shockett PE, Villey IJ, Schatz DG. The RAG proteins and V(D)J recombination: complexes, ends, and transposition. Annu Rev Immunol 2000; 18: 495-527.
13. Zal T, Volkmann A, Stockinger B. Mechanisms of tolerance induction in major histocompatibility complex class II-restricted T cells specific for a blood-borne self-antigen. J Exp Med 1994; 180: 2089-2099.
14. Brocker T, Riedinger M, Karjalainen K. Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. J Exp Med 1997; 185: 541-550.
15. Fujimoto T, Chikahira M, Yoshida S, Ebira H, Hasegawa A, Totsuka A et al. Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of enterovirus 71. Microbiol Immunol 2002; 46: 621-627.
16. Brocker T. The role of dendritic cells in T cell selection and survival. J Leukoc Biol 1999; 66: 331-335.
17. Bensinger SJ, Bandeira A, Jordan MS, Caton AJ, Laufer TM. Major histocompatibility complex class II-positive cortical epithelium mediates the selection of CD4(+)25(+) immunoregulatory T cells. J Exp Med 2001; 194: 427-438.
18. Kyewski B, Klein L. A central role for central tolerance. Annu Rev Immunol 2006; 24: 571-606.
19. Watanabe N, Wang YH, Lee HK, Ito T, Cao W, Liu YJ. Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature 2005; 436: 1181-1185.
20. Bouillet P, Purton JF, Godfrey DI, Zhang LC, Coultas L, Puthalakath H et al. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 2002; 415: 922-926.
21. Schwartz RH. T cell anergy. Annu Rev Immunol 2003; 21: 305-334.
22. de Saint-Vis B, Fugier-Vivier I, Massacrier C, Gaillard C, Vanbervliet B, Ait-Yahia S et al. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J Immunol 1998; 160: 1666-1676.
23. Caux C, Massacrier C, Vanbervliet B, Dubois B, Durand I, Cella M et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood 1997; 90: 1458-1470.
24. Schwartz RH. Acquisition of immunologic self-tolerance. Cell 1989; 57: 1073-1081.
25. Grohmann U, Fallarino F, Silla S, Bianchi R, Belladonna ML, Vacca C et al. CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. J Immunol 2001; 166: 277-283.
26. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 2001; 31: 3388-3393.
27. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995; 182: 389-400.
28. Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 2003; 3: 984-993.
29. Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 1999; 20: 561-567.
30. de Jong EC, Vieira PL, Kalinski P, Schuitemaker JH, Tanaka Y, Wierenga EA et al. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse th cell-polarizing signals. J Immunol 2002; 168: 1704-1709.
31. Jenkins SJ, Mountford AP. Dendritic cells activated with products released by schistosome larvae drive Th2-type immune responses, which can be inhibited by manipulation of CD40 costimulation. Infect Immun 2005; 73: 395-402.
32. Sheng JR, Li L, Ganesh BB, Vasu C, Prabhakar BS, Meriggioli MN. Suppression of experimental autoimmune myasthenia gravis by granulocyte- macrophage colony-stimulating factor is associated with an expansion of FoxP3+ regulatory T cells. J Immunol 2006; 177: 5296-5306.
33. Rutella S, Bonanno G, Procoli A, Mariotti A, de Ritis DG, Curti A et al. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++ IL-12low/neg accessory cells with dendritic-cell features. Blood 2006; 108: 218-227.
34. Morris ES, MacDonald KP, Rowe V, Johnson DH, Banovic T, Clouston AD et al. Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. Blood 2004; 103: 3573-3581.
35. Gonzalez-Rey E, Chorny A, Fernandez-Martin A, Ganea D, Delgado M. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood 2006; 107: 3632-3638.
36. Caux C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten C, Durand I et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994; 180: 1263-1272.
37. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675-680.
38. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-376.
39. Sporri R, Reis e Sousa C. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat Immunol 2005; 6: 163-170.
40. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 2002; 99: 351-358.
41. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194: 769-779.
42. Norbury CC, Chambers BJ, Prescott AR, Ljunggren HG, Watts C. Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur J Immunol 1997; 27: 280-288.
43. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1999; 1: 362-368.
44. Verginis P, Li HS, Carayanniotis G. Tolerogenic semimature dendritic cells suppress experimental autoimmune thyroiditis by activation of thyroglobulin-specific CD4+CD25+ T cells. J Immunol 2005; 174: 7433-7439.
45. Jiang W, Swiggard WJ, Heufler C, Peng M, Mirza A, Steinman RM et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 1995; 375: 151-155.
46. Mahnke K, Guo M, Lee S, Sepulveda H, Swain SL, Nussenzweig M et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol 2000; 151: 673-684.
47. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002; 196: 1627-1638.
48. Scheinecker C, McHugh R, Shevach EM, Germain RN. Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J Exp Med 2002; 196: 1079-1090.
49. Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000; 191: 411-416.
50. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188: 1359-1368.
51. Huang FP, Platt N, Wykes M, Major JR, Powell TJ, Jenkins CD et al. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J Exp Med 2000; 191: 435-444.
52. Hugues S, Mougneau E, Ferlin W, Jeske D, Hofman P, Homann D et al. Tolerance to islet antigens and prevention from diabetes induced by limited apoptosis of pancreatic beta cells. Immunity 2002; 16: 169-181.
53. Rose LM, Latchman DS, Isenberg DA. Apoptosis in peripheral lymphocytes in systemic lupus erythematosus: a review. Br J Rheumatol 1997; 36: 158-163.
54. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 86-89.
55. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000; 191: 423-434.
56. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516-521.
57. Liu K, Iyoda T, Saternus M, Kimura Y, Inaba K, Steinman RM. Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 2002; 196: 1091-1097.
58. Larsen CP, Morris PJ, Austyn JM. Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection. J Exp Med 1990; 171: 307-314.
59. Cobbold SP, Graca L, Lin CY, Adams E, Waldmann H. Regulatory T cells in the induction and maintenance of peripheral transplantation tolerance. Transpl Int 2003; 16: 66-75.
60. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999; 20: 469-473.
61. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191-1193.
62. Belladonna ML, Grohmann U, Guidetti P, Volpi C, Bianchi R, Fioretti MC et al. Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J Immunol 2006; 177: 130-137.
63. Fallarino F, Vacca C, Orabona C, Belladonna ML, Bianchi R, Marshall B et al. Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int Immunol 2002; 14: 65-68.
64. Sakurai K, Zou JP, Tschetter JR, Ward JM, Shearer GM. Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 129: 186-196.
65. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 1097-1101.
66. Ueno A, Cho S, Cheng L, Wang J, Hou S, Nakano H et al. Transient upregulation of IDO in dendritic cells by human chorionic gonadotropin downregulates autoimmune diabetes. Diabetes 2007; 56: 1686-1693.
67. Terness P, Bauer TM, Rose L, Dufter C, Watzlik A, Simon H et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 2002; 196: 447-457.
68. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002; 297: 1867-1870.
69. Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 2005; 310: 850-855.
70. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23: 515-548.
71. Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003; 198: 63-69.
72. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006; 203: 883-895.
73. Subudhi SK, Zhou P, Yerian LM, Chin RK, Lo JC, Anders RA et al. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest 2004; 113: 694-700.
74. Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci USA 2006; 103: 10391-10396.
75. Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 2006; 53: 143-151.
76. Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S et al. B7-H4 overexpression in ovarian tumors. Gynecol Oncol 2006; 100: 44-52.
77. Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, Klemm M et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci USA 2004; 101: 10691-10696.
78. Magnus T, Schreiner B, Korn T, Jack C, Guo H, Antel J et al. Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. J Neurosci 2005; 25: 2537-2546.
79. Shin T, Yoshimura K, Crafton EB, Tsuchiya H, Housseau F, Koseki H et al. In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J Exp Med 2005; 201: 1531-1541.
80. Radhakrishnan S, Celis E, Pease LR. B7-DC cross-linking restores antigen uptake and augments antigen-presenting cell function by matured dendritic cells. Proc Natl Acad Sci USA 2005; 102: 11438-11443.
81. Amend B, Doster H, Lange C, Dubois E, Kalbacher H, Melms A et al. CD4+CD25loCD62Llo T cells mediate CNS autoimmunity after injection of pertussis toxin. J Immunol 2006; 177: 4384-4390.
82. Prasad DV, Richards S, Mai XM, Dong C. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 2003; 18: 863-873.
83. Prasad DV, Nguyen T, Li Z, Yang Y, Duong J, Wang Y et al. Murine B7-H3 is a negative regulator of T cells. J Immunol 2004; 173: 2500-2506.
84. Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003; 18: 849-861.
85. Suh WK, Gajewska BU, Okada H, Gronski MA, Bertram EM, Dawicki W et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol 2003; 4: 899-906.
86. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003; 4: 670-679.
87. Gavrieli M, Sedy J, Nelson CA, Murphy KM. BTLA and HVEM cross talk regulates inhibition and costimulation. Adv Immunol 2006; 92: 157-185.
88. Sedy JR, Gavrieli M, Potter KG, Hurchla MA, Lindsley RC, Hildner K et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 2005; 6: 90-98.
89. Tang Q, Bluestone JA. Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev 2006; 212: 217-237.
90. Shevach EM, DiPaolo RA, Andersson J, Zhao DM, Stephens GL, Thornton AM. The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol Rev 2006; 212: 60-73.
91. Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000; 164: 183-190.
92. Karim M, Feng G, Wood KJ, Bushell AR. CD25+CD4+ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigen-specific reactivation in vivo is critical for bystander regulation. Blood 2005; 105: 4871-4877.
93. Luo X, Tarbell KV, Yang H, Pothoven K, Bailey SL, Ding R et al. Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 2007; 104: 2821-2826.
94. Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 2005; 201: 1061-1067.
95. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998; 188: 287-296.
96. Shevach EM. Regulatory T cells in autoimmmunity*. Annu Rev Immunol 2000; 18: 423-449.
97. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-336.
98. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001; 27: 18-20.
99. Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-Pedersen A et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 2006; 103: 6659-6664.
100. Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, Rudensky AY. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 2007; 445: 936-940.
101. Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 2007; 445: 771-775.
102. Feger U, Luther C, Poeschel S, Melms A, Tolosa E, Wiendl H. Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin Exp Immunol 2007; 147: 412-418.
103. Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007; 37: 129-138.
104. Lin W, Haribhai D, Relland LM, Truong N, Carlson MR, Williams CB et al. Regulatory T cell development in the absence of functional Foxp3. Nat Immunol 2007; 8: 359-368.
105. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203: 1701-1711.
106. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol Rev 2001; 182: 68-79.
107. Ito T, Yang M, Wang YH, Lande R, Gregorio J, Perng OA et al. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med 2007; 204: 105-115.
108. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001; 2: 725-731.
109. Akbari O, Freeman GJ, Meyer EH, Greenfield EA, Chang TT, Sharpe AH et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med 2002; 8: 1024-1032.
110. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994; 265: 1237-1240.
111. Iwasaki A, Kelsall BL. Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells. J Exp Med 1999; 190: 229-239.
112. Yamazaki S, Iyoda T, Tarbell K, Olson K, Velinzon K, Inaba K et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003; 198: 235-247.
113. Mahnke K, Qian Y, Knop J, Enk AH. Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood 2003; 101: 4862-4869.
114. Oldenhove G, de Heusch M, Urbain-Vansanten G, Urbain J, Maliszewski C, Leo O et al. CD4+ CD25+ regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo. J Exp Med 2003; 198: 259-266.
115. Walker LS, Chodos A, Eggena M, Dooms H, Abbas AK. Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med 2003; 198: 249-258.
116. Brinster C, Shevach EM. Bone marrow-derived dendritic cells reverse the anergic state of CD4+CD25+ T cells without reversing their suppressive function. J Immunol 2005; 175: 7332-7340.
117. Tarbell KV, Yamazaki S, Steinman RM. The interactions of dendritic cells with antigen-specific, regulatory T cells that suppress autoimmunity. Semin Immunol 2006; 18: 93-102.
118. Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 2004; 199: 1467-1477.
119. Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P et al. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 2006; 7: 83-92.
120. Tadokoro CE, Shakhar G, Shen S, Ding Y, Lino AC, Maraver A et al. Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo. J Exp Med 2006; 203: 505-511.
121. Ochando JC, Yopp AC, Yang Y, Garin A, Li Y, Boros P et al. Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3+ regulatory T cells. J Immunol 2005; 174: 6993-7005.
122. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001; 1: 220-228.
123. Wells AD, Walsh MC, Bluestone JA, Turka LA. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J Clin Invest 2001; 108: 895-903.
124. Kumanogoh A, Wang X, Lee I, Watanabe C, Kamanaka M, Shi W et al. Increased T cell autoreactivity in the absence of CD40-CD40 ligand interactions: a role of CD40 in regulatory T cell development. J Immunol 2001; 166: 353-360.
125. Lin CH, Hunig T. Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol 2003; 33: 626-638.
126. Sanchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, Sabatos CA et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 2003; 4: 1093-1101.
127. Godfrey WR, Ge YG, Spoden DJ, Levine BL, June CH, Blazar BR et al. In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 2004; 104: 453-461.
128. Lechler RI, Batchelor JR. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med 1982; 155: 31-41.
129. Morelli AE, Thomson AW. Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol Rev 2003; 196: 125-146.
130. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1: 1297-1302.
131. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61: 6451-6458.
132. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003; 3: 630-641.
133. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002; 195: 1279-1288.
134. Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 2004; 4: 24-34.
135. Maksimow M, Miiluniemi M, Marttila-Ichihara F, Jalkanen S, Hanninen A. Antigen targeting to endosomal pathway in dendritic cell vaccination activates regulatory T cells and attenuates tumor immunity. Blood 2006; 108: 1298-1305.
136. Veldhoen M, Moncrieffe H, Hocking RJ, Atkins CJ, Stockinger B. Modulation of dendritic cell function by naive and regulatory CD4+ T cells. J Immunol 2006; 176: 6202-6210.
137. Lewkowich IP, Herman NS, Schleifer KW, Dance MP, Chen BL, Dienger KM et al. CD4+CD25+ T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function. J Exp Med 2005; 202: 1549-1561.
138. Houot R, Perrot I, Garcia E, Durand I, Lebecque S. Human CD4+CD25high regulatory T cells modulate myeloid but not plasmacytoid dendritic cells activation. J Immunol 2006; 176: 5293-5298.
139. Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Cutting edge: human CD4+CD25+ Tcells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 2004; 172: 4676-4680.
140. Min WP, Zhou D, Ichim TE, Strejan GH, Xia X, Yang J et al. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol 2003; 170: 1304-1312.
141. Cederbom L, Hall H, Ivars F. CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 2000; 30: 1538-1543.
142. Fallarino F, Bianchi R, Orabona C, Vacca C, Belladonna ML, Fioretti MC et al. CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med 2004; 200: 1051-1062.